Business
Change of Adviser
Change of Adviser.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 9909Q\n Angle PLC\n 02 November 2021\n \n \n \n \n \n \n \n \n For immediate release\n \n \n \n \n 2 November 2021\n \n \n \n \n \n \n \n \n \n ANGLE plc (\"the Company\")\n \n \n \n \n \n Change of advisers\n \n \n \n \n \n ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce the appointments of Berenberg as its Nominated Adviser and Joint Broker and Jefferies as its Joint Broker with immediate effect.\n \n \n \n \n \n For further information:\n \n \n \n \n \n \n \n \n \n ANGLE plc\n \n \n \n \n +44 (0) 1483 343434\n \n \n \n \n \n \n Andrew Newland, Chief Executive\n \n \n Ian Griffiths, Finance Director\n \n \n Andrew Holder, Head of Investor Relations\n \n \n \n \n \n \n \n \n \n \n Berenberg (NOMAD and Joint Broker)\n \n \n Toby Flaux, Jen Clarke, Milo Bonser, Shiv Dave \n \n \n \n \n \n +44 (0) 20 3207 7800\n \n \n \n \n \n \n Jefferies (Joint Broker)\n \n \n Max Jones, Thomas Bective\n \n \n \n \n \n +44 (0) 20 7029 8000\n \n \n \n \n \n \n \n \n \n FTI Consulting\n \n \n Simon Conway, Ciara Martin\n \n \n Matthew Ventimiglia (US) \n \n \n \n \n \n \n \n +44 (0) 203 727 1000\n \n \n +1 (212) 850 5624\n \n \n \n \n \n \n \n \n \n For Frequently Used Terms, please see the Company's website on \n \n https://angleplc.com/investor-relations/glossary/\n \n \n \n \n \n \n Notes for editors\n \n \n \n \n \n \n About ANGLE plc\n \n \n \n www.angleplc.com\n \n \n \n ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent protected platforms include a circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.\n \n \n \n \n \n ANGLE's cell separation technology is called the Parsortix® system, and it enables a liquid biopsy (a simple blood test) to be used to provide the cells of interest to the user in a format suitable for multiple types of downstream analyses. The system is based on a microfluidic device that captures cells based on a combination of their size and compressibility. The system is epitope independent and can capture all types of CTCs as well as CTC clusters in a viable form (alive)....